Aptamer-target interaction descriptor
Aptamer-target interaction information
Interaction ID: 595
Aptamer sequence: GGAUAAUAGCCGUAGGUUGCGAAAGCGACCCUGAUGAGCCUUUAGGGCCAAGUGUGGUGAAAGACACACUCGAAACGGUAGCGAGAGCUC
Target unique ID: 19236
Aptamer ID Aptamer descriptor Target chemistry Target name Affinity Binding Conditions/Buffer PubMed ID
Apta_562 AR3 Molecule Cyclic cmp N/A 50 mM Tris-HCl, pH 7.5, 20 mM MgCl2 11283591
Structure information of aptamer
Aptamer Sequence: GGAUAAUAGCCGUAGGUUGCGAAAGCGACCCUGAUGAGCCUUUAGGGCCAAGUGUGGUGAAAGACACACUCGAAACGGUAGCGAGAGCUC
The optimal secondary structure in dot-bracket notation: ........(((((.((((((....))))))....((.((((...))))))((((((........))))))....)))))(((....))).
The centroid secondary structure in dot-bracket notation: ........(((((.((((((....))))))....((.((((...))))))((((((........))))))....)))))(((....))).
The MFE structure
The Centroid structure
The mountain plot representation
Aptamer information
Type Detail Type Detail
Aptamer ID Apta_562 Description AR3
Aptamer chemistry RNA Length 90 nt
GC content 53.3% Molecular weight 29,205.45 Da
Molarity of 1 μg/μl solution 34.24 μM Number of G-quadruplexes No QGRS found
G-Score N/A Function Aptasensor
Sequence GGAUAAUAGCCGUAGGUUGCGAAAGCGACCCUGAUGAGCCUUUAGGGCCAAGUGUGGUGAAAGACACACUCGAAACGGUAGCGAGAGCUC
Applications Recognition of cAMP
Target information
Type Detail Type Detail
PubChem ID 19236 Molecular name Cyclic cmp
Molecular formula C9H12N3O7P Molecular weight 305.18
IUPAC name 1-[(4aR,6R,7R,7aS)-2,7-dihydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]-4-aminopyrimidin-2-one InChIKey WCPTXJJVVDAEMW-XVFCMESISA-N
LogP -1.4 Topological polar surface area 146.13
Hydrogen bond acceptor 9 Hydrogen bond donor 3

Synonym(s):
CYCLIC CMP; cCMP; 3616-08-8; 3',5'-Cyclic CMP; Cytidine, cyclic 3',5'-(hydrogen phosphate); CHEBI:17065; Cytidine 3',5'-cyclic monophosphate; cytidine 3',5'-(hydrogen phosphate); 1-[(4aR,6R,7R,7aS)-2,7-dihydroxy-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]-4-aminopyrimidin-2-one; 4-Amino-1-[(2s,4ar,6r,7r,7as)-2,7-Dihydroxy-2-Oxidotetrahydro-4h-Furo[3,2-D][1,3,2]dioxaphosphinin-6-Yl]pyrimidin-2(1h)-One; CC7; Cyclic CMP, 7; CYTIDINE 3':5'-CYCLIC MONOPHOSPHATE; CHEMBL72442; C9H12N3O7P; GTPL6261; SCHEMBL1331888; BDBM31910; DTXSID10957571; Cytidine-3',5'-cyclicmonophosphate; ZINC4095499; 6570AH; Cytidine cyclic-3',5'-monophosphate; Cytidine-3',5'-cyclic monophosphate; C00941; Q27076941; 2,7-Dihydroxy-6-(2-hydroxy-4-iminopyrimidin-1(4H)-yl)tetrahydro-2H,4H-2lambda~5~-furo[3,2-d][1,3,2]dioxaphosphinin-2-one; 4-amino-1-[(1S,6R,8R,9R)-3,9-dihydroxy-3-oxo-2,4,7-trioxa-3$l^{5}-phosphabicyclo[4.3.0]nonan-8-yl]pyrimidin-2-one

Activity data

No relevant experimental diagram

Interaction ID 595
Target type Molecule
Target unique ID 19236
Activity N/A
Binding Conditions/Buffer

50 mM Tris-HCl, pH 7.5, 20 mM MgCl2

Assay

N/A

PubMed ID 11283591
Similar aptamers
Aptamer ID Aptamer chemistry Sequence Similarity
Apta_566 RNA GGAUAAUAGCCGUAGGUUGCGAAAGCGACCCUGAUGAGCCCUGCGAUGCAGAAAGGUGCUGACGACACAUCGAAACGGUAGCGAGAGCUC
85.56%
Apta_613 RNA GGAUAAUAGCCGUAGGUUGCGAAAGCGACCCUGAUGAGCCUUAGGAUAUGCAUGAUGCAGAAGGACGUCGAAACGGUAGCGAGAGCUC
84.44%
Apta_561 RNA GGAUAAUAGCCGUAGGUUGCGAAAGCGACCCUGAUGAGCCUGUGGAAACAGACGUGGCACAUGACUACGUCGAAACGGUAGCGAGAGCUC
83.33%
Apta_710 RNA GGAUAAUAGCCGUAGGUUGCGAAAGCGACCCUGAUGAGUCUGGAUACCAUGCAUGAUGCACCUUGGCAGUCUUACGAAACGGUAGCGAGAGCUC 78.72%
Apta_563 RNA GGAUAAUAGCCGUAGGUUGCGAAAGCGACCCUGAUGAGAAAGCCAAAGCCGUAGCGCAGAUGAUCUCGCCAUCAGUACCGAAACGGUAGCGAGAGCUC 76.53%
Apta_874 RNA GGAUAAUAGCCGUAGGUUGCGAAAGCGACCCUGAUGAGCCUUAGGAUAUGUCUGGAUACCAUGCAUGAUGCACCUUGGCAGUCUUACAGAAGGACGUCGAAACGGUAGCGAGAGCUC 72.65%
Apta_559 RNA GGAUGUCCAGUCGCUUGCAAUGCCCUUUUAGACCCUGAUGAGGAUCAUCGGACUUUGUCCUGUGGAGUAAGAUCGCGAAACGGUGAAAGCCGUAGGUCU 56.57%
Apta_551 RNA GGAUGUCCAGUCGCUUGCAAUGCCCUUUUAGACCCUGAUGAGCGGUGCUAGUUAGUUGCAGUUUCGGUUGUUACGCGAAACGGUGAAAGCCGUAGGUCU 54.55%
Apta_416 RNA GGACCUCGGCGAAAGCCGGUAACGCCACAAGUCGGAGGGUAAGAUCUGACAGGAACUGGGUGACGGAGGUUAGGUGC 53.33%
Apta_38 RNA GGUAGAUACGAUGGAUACCCCCUGUGGCCCGUCAACACAGGGGAAGUGGCAUGACGCGCAGCCA 52.22%
Apta_295 RNA AUACCAGCUUAUUCAAUUGCCUGAAAAGCUAUCGCCCAAUUCGCAGUGAUAUCCUUUAAGAUAGUAAGUGCAAUCU 52.22%
Apta_460 RNA GGAUGGCAGCGGAGAGUUGCUUGGAAUGCGUUAUAGUCUCUUAGGUGUGUACAGCCCACACCACUCUCC 52.22%
Apta_576 RNA GGCACCAAAGCUGAAGUAGCGGGAUAACUCAAAUUACUUUAGGUGUAUGAAGGUGAAACUAGCAAUGAA 52.22%
Apta_766 RNA GGUUACCAGCCUUCACUGCGGACGGACAGAGAGUGCAACCUGCCGUGCCGCACCACGGUCGGUCACAC 52.22%
Apta_280 RNA GAUAAUACGACUCACUAUAGGGUUCACUGCAGACUUGACGAAGCUUGCAGAAAAGGGGGAAGAAGAGGGUGAUUCAGGCGAGAGAAUGGAUCCACAUCUACGAAUUC 51.40%
Apta_123 RNA GGGAGAAAGGGAAGCUUGAGCAGCAGGAGGGCCGGCGUUAGGGUUAGCGAGCCGAUUGAAAGAAGAAGGAACGAGCGUACGGAUCCGAUC 51.11%
Apta_296 RNA AUACCAGCUUAUUCAAUUGCCUGAAAACCUGGUCUCUCUGUCAGCAAAGACUAUGTUGAGAUAGUAAGUGCAAUCU 51.11%
Apta_301 RNA AUACCAGCUUAUUCAAUUGCCUGAAAAGUUGAACUCCAAAUACGCGCUGAGAUAGUAAGUGCAAUCU 51.11%
Apta_305 RNA GGGAGGACGAUGCGGAUCGCCCUGAACCGGCCCAGCAGACUGCUGACGGCACGAUCCGCAUCGUCCUCCC 51.11%
Apta_414 RNA GGGAGGACGAUGCGGCCGAUUAGAACUGGGCUGAGGCGUUCUGCAUUUCGGUGAUCAGACGACUCGCUGAGGAUCCGAGA 51.11%